Swiss pharmaceutical company Novartis is significantly expanding the scale and complexity of its operations in India, repositioning its local development centers as central pillars of its global strategy. The company has effectively converted its presence in India to a Global Capability Center (GCC). The company is focusing its research efforts...
Amgen Invests $200M in India Tech Center
Thousand Oaks, CA-headquartered pharmaceutical company Amgen, announced plans to invest $200 million in 2025 to establish its new technology and innovation center in Hyderabad, southern India. CEO Robert Bradway made this announcement during the site's inauguration on Monday, Feb 24, adding that significant additional investments are planned for future years....
India Gets Recognition as a Global Clinical Trials Hub
India is rapidly emerging as a premier global destination for multinational pharmaceutical companies to conduct clinical trials. This marks a significant shift in the industry landscape, driven by India's simplified, accessible, and expedited clinical trial processes. Over the past decade, India has experienced substantial growth of 15-18% in Phase 2...
Novartis to Evaluate India for Additional Manufacturing Capabilities
Swiss pharma company Novartis will evaluate India to scale up its manufacturing capabilities and technology advancements, in future, if needed, said Vas Narasimhan, M.D., global Chief Executive Officer of Novartis. India is amongst a handful of countries in the world that have a broad Novartis footprint covering early research, drug...
Novartis Conducted Clinical Trials in India for Covid Drug Ruxolitinib
Swiss major Novartis sought regulatory approval in India to initiate Phase III clinical trials for its drug, Ruxolitinib used in the treatment of Covid 19. These trials were part of a global study that the company started in May to evaluate the use of Ruxolitinib (sold as Jakavi) for treatment...
India's Aurobindo Buys Novartis' Dermatology business
Hyderabad, India-based Aurobindo Pharma signed a definitive agreement to acquire certain assets from Sandoz Inc., U.S.A., a Novartis division, for a consideration of $900 million. The proposed acquisition will be on a debt-free and cash-free basis, and comprises the dermatology business and a portfolio of oral solid products along with commercial...